Search
Close this search box.

Bill Meury named CEO of Anthos

ARTICLE | Management Tracks

Plus: Fujimoto to lead Takeda-Astellas-Sumitomo’s JV, and updates from Sofinnova Partners, SystImmune, Amarna and Cytonus

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst 

April 23, 2024 12:35 AM UTC

Anthos Therapeutics Inc. named Bill Meury to succeed founding CEO John Glasspool, who will join Blackstone Life Sciences as an operating adviser. Meury, who was CEO of Karuna Therapeutics Inc. before it was acquired by Bristol Myers Squibb Co. (NYSE:BMY), will also join Anthos’ board. Blackstone Life Sciences founded Anthos, a cardiovascular disease company, alongside Novartis AG (SIX:NOVN; NYSE:NVS) in 2019. 

Toshio Fujimoto will become CEO of a joint venture of  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK), Astellas Pharma Inc. (Tokyo:4503) and Sumitomo Mitsui Banking Corp. that will incubate early discovery programs primarily originating from Japan. Fujimoto was CEO of iPark Institute Co. Ltd., the company in charge of managing Shonan Health Innovation Park, a pharmaceutical-initiated science park established in 2018…